% | $
Quotes you view appear here for quick access.

OncoSec Medical Incorporated Message Board

  • mainecoasttover mainecoasttover Oct 15, 2012 1:37 PM Flag

    i dumped ONCS. All in CUR



    This company looks like a joke IMHO

    This topic is deleted.
    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • well we didn't close worth crap , but we are trading in tight 1 to 2 cent range now. We might have to wait for trials to see any significant gain.

      Sentiment: Strong Buy

    • LOL, I rode the wave on CUR during that $1.96 run weeks ago and still have position in it right now, unfortunately even as a shareholder of CUR I can tell you their upside in the short/mid-term have minimal catalysts... it's also highly effected by the presidential election btw, the next catalyst for them is if Obama wins.

      Sentiment: Hold

    • they aren't even in phase 1 trial yet. They have some response in rats . RATS ! ONCS on the other hand has had successful phase 1 trial and is now conducting 3 phase 2 trials. Have fun kids !

      Sentiment: Strong Buy

    • While the cures that most biotechnology stocks promise offer excitement, investors' joy over some recent developments at stem-cell technology company Neuralstem is a downright head-scratcher.

      Neuralstem, whose technology enables the ability to produce neural stem cells of the brain and spinal cord, recently released its findings on its early stage safety clinical trial for amyotrophic lateral sclerosis. The results showed the treatment was well-tolerated, but this initial test had more or less nothing to do with efficacy. Yet, the stock, has nearly tripled from its lows set in August, which included a $7 million dilutive secondary offering in September.

      Realistically, given Neuralstem's annual loss rate, and including its recent secondary offering, it likely has enough cash for just 12 more months. Just yesterday I highlighted the make-or-break stem-cell company Aastrom Biosciences (Nasdaq: ASTM ) as my speculative choice within the sector. Aastrom reported positive phase 2 results on its critical limb ischemia drug, ixmyelocel-T, in November, and looks significantly more promising from a pipeline and balance sheet perspective than Neuralstem. Make no mistake, government regulation make the entire sector a gamble, but Neuralstem sure looks like a suckers bet to me.

    • sxsess Oct 15, 2012 1:55 PM Flag

      I did..Your a joke.

      Sentiment: Strong Buy

3.28+0.02(+0.61%)Nov 27 12:59 PMEST